These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 2250356)

  • 1. [Tolerance dosage of normal tissues by radiotherapy combined with chemotherapy in the group of patients].
    Hishikawa Y
    Gan No Rinsho; 1990 Oct; 36(13):2353-6. PubMed ID: 2250356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Normal tissue tolerance to external beam radiation therapy: bone marrow].
    Drouet F; Lagrange JL
    Cancer Radiother; 2010 Jul; 14(4-5):392-404. PubMed ID: 20598617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternation of chemotherapy and radiotherapy in cancer management. I. Summary of the Division of Cancer Treatment Workshop.
    Looney WB; Goldie JH; Little JB; Hopkins HA; Read EJ; Wittes R
    Cancer Treat Rep; 1985; 69(7-8):769-75. PubMed ID: 4016787
    [No Abstract]   [Full Text] [Related]  

  • 4. [How to enhance the efficacy of radiotherapy].
    Calais G
    Rev Prat; 1994 Apr; 44(8):1021-5. PubMed ID: 7939318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors].
    Altmann S; Hoffmanns H
    Strahlenther Onkol; 1999 Nov; 175 Suppl 4():30-3. PubMed ID: 10584138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Standardization and optimization of the radiotherapy schedule from the standpoint of the tolerance dose of the normal tissues].
    Morita K
    Gan No Rinsho; 1985 Sep; 31(12):1512-9. PubMed ID: 4079039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor control probability (TCP) and normal tissue complication probability (NTCP) in head and neck cancer.
    Grégoire V
    Rays; 2005; 30(2):105-8. PubMed ID: 16294902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Should positive phase III clinical trial data be required before proton beam therapy is more widely adopted? No.
    Suit H; Kooy H; Trofimov A; Farr J; Munzenrider J; DeLaney T; Loeffler J; Clasie B; Safai S; Paganetti H
    Radiother Oncol; 2008 Feb; 86(2):148-53. PubMed ID: 18237800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comments on the review entitled "Radiobiological features of anticancer treatments involving synchrotron radiation: outcome and perspectives"].
    Elleaume H; Rousseau J; Adam JF; Estève F
    Cancer Radiother; 2011 Apr; 15(2):161-4; author reply 164-7. PubMed ID: 21146436
    [No Abstract]   [Full Text] [Related]  

  • 10. New treatment modalities in radiation therapy.
    Holland J
    J Intraven Nurs; 2001; 24(2):95-101. PubMed ID: 11836839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New concepts for phase I trials: evaluating new drugs combined with radiation therapy.
    Deutsch E; Soria JC; Armand JP
    Nat Clin Pract Oncol; 2005 Sep; 2(9):456-65. PubMed ID: 16264990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is one Gy equal to one Gy in chemo-radiotherapy or hormono-radiotherapy?
    Corvò R; Berretta L; Andretta V
    Rays; 2004; 29(3):287-9. PubMed ID: 15603300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Combined modality treatment of chemotherapy and radiotherapy for unresectable non-small cell lung cancer].
    Kubota K
    Gan To Kagaku Ryoho; 1997 Oct; 24 Suppl 3():384-9. PubMed ID: 9369912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxicity after cervical cancer treatment using radiotherapy and chemotherapy.
    Jones B
    Clin Oncol (R Coll Radiol); 2009 Feb; 21(1):56-63. PubMed ID: 19046625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Interactive determination of the parameters of mathematical models for planning radiotherapy of malignant tumors. I. Mathematical models for calculating dose tolerance, adequate doses and the likelihood of development of radiation complications in normal organs and tissues].
    Klepper LIa
    Med Tekh; 2000; (4):37-41. PubMed ID: 10984881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Late complications of chemoradiotherapeutic combinations: fundamental aspects and clinical experience].
    Balosso J; Minne JF; Touboul E
    Bull Cancer Radiother; 1995; 82(2):101-12. PubMed ID: 7546881
    [No Abstract]   [Full Text] [Related]  

  • 18. [How tolerant are partial dose values? Some additional remarks on the concept of a tolerance dose].
    Jensen JM; Melchert UH; Ihnen E
    Strahlenther Onkol; 1992 Nov; 168(11):640-5. PubMed ID: 1455292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prognostic factors of the probability of the occurrence of complications in the radiation therapy of malignant neoplasms].
    Pavlov AS; Datsenko VS; Fadeeva MA; Zamiatin OA; Kizhaev EV
    Vopr Onkol; 1980; 26(3):3-8. PubMed ID: 7368653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining EGFR inhibitors with radiation or chemotherapy: will preclinical studies predict clinical results?
    Harari PM; Huang SM
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):976-83. PubMed ID: 14967459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.